T2 Biosystems T2SARS-CoV-2™ Panel Detects Omicron Variant
December 01 2021 - 9:00AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens, today announced that its
T2SARS-CoV-2™ Panel detects the Omicron COVID-19 variant
(B.1.1.529).
The World Health Organization has designated the Omicron variant
as a SARS-CoV-2 “variant of concern” with more than 30 mutations in
the spike protein region. The variant was initially identified in
South Africa and has already been detected across 20 countries.
To confirm that the T2SARS-CoV-2 Panel would detect the new
Omicron (B.1.1.529) variant, in silico analysis was performed using
sequences in the GISAID database. SARS-CoV-2 (B.1.1.529) sequences
were evaluated for alignment with primer and probe sequences from
T2SARS-CoV-2 Panel. These analyses demonstrated that none of the
new B.1.1.529 mutations occur within the region targeted by the
T2SARS-CoV-2 Panel.
“We are proud to announce our technology is capable of detecting
additional COVID-19 variants including Omicron, enabling healthcare
providers with the confidence to make more informed decisions about
their patients’ health,” said T2 Biosystems’ Chairman and CEO, John
Sperzel.
The T2SARS-CoV-2 Panel, which has demonstrated clinical
sensitivity of 95 percent and specificity of 100 percent, provides
results in under two hours utilizing an upper respiratory swab
sample. The test runs on the Company’s FDA-cleared and
fully-automated T2Dx® Instrument, which is capable of performing
seven tests simultaneously and up to sixty samples per day.
The same T2Dx Instrument is also capable of running the
FDA-cleared T2Bacteria® Panel and T2Candida® Panel. These panels
are the only FDA-cleared assays for the detection of sepsis-causing
bacterial and fungal pathogens directly from whole blood in three
to five hours, without the need to wait days for blood culture
results. By providing quicker results, the panels enable clinicians
to target therapy faster for their patients suspected of sepsis,
often before the second dose of antimicrobial medicine is
administered, leading to better patient outcomes, improved
antimicrobial stewardship, and reductions in length of stay in the
hospital.
These additional panels remain especially clinically relevant
during the pandemic, as data suggests that the COVID-19 virus can
lead to sepsis, and death.
About T2 BiosystemsT2 Biosystems, a leader in
the rapid detection of sepsis-causing pathogens, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, T2Candida®
Panel, the T2Bacteria® Panel, the T2Resistance® Panel, and the
T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic
Resonance (T2MR®) technology. T2 Biosystems has an active pipeline
of future products, including the T2Cauris™ Panel, and T2Lyme™
Panel, as well as additional products for the detection of
bacterial and fungal pathogens and associated antimicrobial
resistance markers, and biothreat pathogens.
Media Contact:Meagan Dominick, Vault
Communicationsmdominick@vaultcommunications.com 773-369-4255
Investor Contact:Philip Trip Taylor, Gilmartin
Groupphilip@gilmartinIR.com 415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024